Hospital
Welia Health
Welia Health was paid $14.43M by Medicaid between Jan 2018 and Dec 2024, across 107 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoWELIA HEALTH
MORA, MN 55051
MORA, MN 55051
33aNPI1528031390assigned 02/10/2006
33bProvider typeCritical Access Hospital
28Total paid$14.43M
24GClaims141,178
24DCodes billed107
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Minnesota
Rank by total paid#2 of 68
Median peer was paid$798K
This provider vs. median18×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,119 | $306K | |
| 2019 | 17,684 | $1.58M | |
| 2020 | 15,225 | $1.32M | |
| 2021 | 26,218 | $2.46M | |
| 2022 | 29,333 | $3.19M | |
| 2023 | 30,824 | $3.49M | |
| 2024incomplete | 15,775 | $2.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 23,211 | 18,224 | $3.89M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 25% | 8,829 | 6,565 | $3.56M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 15,276 | 12,108 | $2.99M |
| 80053 | Comprehensive metabolic panel | 4.9% | 4,596 | 4,230 | $705K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 12,063 | 11,105 | $339K |
| 36415 | Collection of venous blood by venipuncture | 2.3% | 27,162 | 23,949 | $338K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.8% | 3,088 | 2,892 | $255K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 1,928 | 1,871 | $217K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 1,850 | 804 | $212K |
| A0425 | Ground mileage, per statute mile | 1.1% | 979 | 758 | $154K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,453 | 1,252 | $121K |
| 80306 | <1% | 2,637 | 2,269 | $119K |
95 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,831 | $113K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,573 | $87K |
| 71045 | Radiologic examination, chest; single view | <1% | 785 | $86K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,899 | $84K |
| 81001 | <1% | 3,112 | $82K | |
| 84484 | <1% | 750 | $78K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,530 | $75K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 645 | $67K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 122 | $67K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,532 | $66K |
| 76801 | <1% | 156 | $54K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,369 | $52K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 157 | $40K |
| 64483 | <1% | 62 | $36K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 532 | $32K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 588 | $30K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,675 | $28K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 985 | $28K |
| 81025 | <1% | 835 | $28K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 332 | $22K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 731 | $21K |
| 86803 | <1% | 403 | $19K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 378 | $18K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 823 | $18K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 247 | $17K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 440 | $16K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 625 | $16K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 446 | $16K |
| 83690 | <1% | 676 | $15K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 17 | $14K |
| 86780 | <1% | 454 | $14K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 13 | $13K |
| 85027 | <1% | 724 | $12K | |
| 87210 | <1% | 953 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 372 | $12K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 13 | $10K |
| 82077 | <1% | 168 | $10K | |
| 83605 | <1% | 238 | $9K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 401 | $7K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 242 | $7K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 140 | $6K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 66 | $6K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 46 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 273 | $5K |
| 92015 | Determination of refractive state | <1% | 430 | $4K |
| 86787 | <1% | 78 | $4K | |
| 86900 | <1% | 118 | $4K | |
| 82803 | <1% | 34 | $3K | |
| 82248 | <1% | 110 | $3K | |
| 86850 | <1% | 117 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 115 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 31 | $3K |
| 81003 | <1% | 126 | $3K | |
| 86901 | <1% | 118 | $3K | |
| 96127 | <1% | 96 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 268 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 292 | $3K |
| 86762 | <1% | 63 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 278 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 66 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 12 | $2K |
| 85610 | <1% | 220 | $2K | |
| 86140 | <1% | 108 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 398 | $2K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 42 | $2K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 58 | $2K |
| 80061 | Lipid panel | <1% | 49 | $2K |
| 84703 | <1% | 41 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 40 | $1K |
| 92341 | <1% | 75 | $1K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 1,196 | $1K |
| 80179 | <1% | 31 | $1K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 26 | $1K |
| 80143 | <1% | 30 | $1K | |
| J3490 | Unclassified drugs | <1% | 197 | $1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 101 | $1K |
| 85018 | <1% | 83 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 183 | $1K |
| 82378 | <1% | 15 | $791.03 | |
| 87340 | <1% | 26 | $752.03 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 98 | $719.92 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 13 | $544.23 |
| 82565 | <1% | 71 | $514.76 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 58 | $462.96 |
| 87467 | <1% | 13 | $443.09 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 46 | $302.82 |
| 86695 | <1% | 12 | $249.43 | |
| 86696 | <1% | 12 | $249.43 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 12 | $190.37 |
| 84132 | <1% | 30 | $132.86 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13 | $94.53 |
| 83735 | <1% | 14 | $86.89 | |
| 84295 | <1% | 15 | $64.03 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 57 | $44.52 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialULSETH, RANDY (CEO)
| Provider | Location | Paid |
|---|---|---|
| Welia Health | Pine City, MN | $6.19M |
| Welia Health | Mora, MN | $2.77M |
| Welia Health | Hinckley, MN | $1.64M |
| Welia Health | Mora, MN | $676.29 |
| Welia Health | Pine City, MN | $275.09 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.